Arterial hypertension and cancer

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

(2016)   JOURNAL OF HYPERTENSION

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

(2015)   Oncotarget

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

(2015) Eddy Pasquier et al.   Oncotarget

VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration

(2013) Peter Carmeliet et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy

(2012) Giorgio Santoni et al.   BRITISH JOURNAL OF PHARMACOLOGY

Beta blocker use and colorectal cancer risk

(2012) Lina Jansen et al.   CANCER

Which, if any, antihypertensive agents cause cancer?

(2012) Amita Singh et al.   CURRENT OPINION IN CARDIOLOGY

Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts

(2012) Q. Wang et al.   DISEASES OF THE ESOPHAGUS

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Meta-Analysis of Randomized Controlled Trials on Effect of Angiotensin-Converting Enzyme Inhibitors on Cancer Risk

(2011) Ilke Sipahi et al.   AMERICAN JOURNAL OF CARDIOLOGY

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma

(2011) Vincenzo De Giorgi et al.   ARCHIVES OF INTERNAL MEDICINE

Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies

(2011) C. Yoon et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins

(2011) Young Kwang Chae et al.   CANCER INVESTIGATION

Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System

(2011) Babak Nazer et al.   CIRCULATION

Molecular Pathways: Beta-Adrenergic Signaling in Cancer: Figure 1.

(2011) Steven W. Cole et al.   CLINICAL CANCER RESEARCH

Angiotensin Peptides and Lung Cancer

(2011) P. E. Gallagher et al.   CURRENT CANCER DRUG TARGETS

The renin–angiotensin system in the breast and breast cancer

(2011) Gavin P Vinson et al.   ENDOCRINE-RELATED CANCER

Beta Blockers and Breast Cancer Mortality: A Population- Based Study

(2011) Thomas I. Barron et al.   JOURNAL OF CLINICAL ONCOLOGY

Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer

(2011) Amal Melhem-Bertrandt et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiotensin receptor antagonists and increased risk of cancer. Further evidence against

(2011) Giuseppe Mancia   JOURNAL OF HYPERTENSION

Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review

(2011) D. Keefe et al.   ONCOLOGIST

Prevention of pancreatic cancer by the beta-blocker propranolol

(2010) Hussein A. Al-Wadei et al.   ANTI-CANCER DRUGS

β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-κB and AP-1

(2010) Dong Zhang et al.   CANCER BIOLOGY & THERAPY

High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study

(2010) Rikje Ruiter et al.   EUROPEAN JOURNAL OF CANCER

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

(2010) Mariëtte H.W. Kappers et al.   HYPERTENSION

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

(2010) Michael L. Maitland et al.   JNCI-Journal of the National Cancer Institute

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

(2010) Sripal Bangalore et al.   LANCET ONCOLOGY

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

(2009) Faina Gurevich et al.   AMERICAN JOURNAL OF MEDICINE

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

(2009) Hassane Izzedine et al.   EUROPEAN JOURNAL OF CANCER

Thiazide Effects and Adverse Effects

(2009) David H. Ellison et al.   HYPERTENSION

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials

(2009) Craig I Coleman et al.   JOURNAL OF HYPERTENSION

Use of photosensitising diuretics and risk of skin cancer: a population-based case–control study

(2008) A Ø Jensen et al.   BRITISH JOURNAL OF CANCER

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

Home Blood-Pressure Monitoring in Patients Receiving Sunitinib

(2008) Michel Azizi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Pancreatic Cancer Cell Proliferation by Propranolol Occurs Through Apoptosis Induction

(2008) Dong Zhang et al.   PANCREAS

Long-term use of antihypertensive drugs and risk of cancer

(2008) Themistocles L. Assimes et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

(2007) J.-J. Mourad et al.   ANNALS OF ONCOLOGY